Teva, Dr. Reddy's settle in carvedilol case

NEW YORK Teva has settled a case against Dr. Reddy’s concerning its patent on carvedilol, the active ingredient in GlaxoSmithKline’s heart drug Coreg.

Teva started filing suits last June to protect its ‘997, ‘184, ‘942 and ‘008 patents relating to carvedilol.

The defendants in the cases, including Ranbaxy Laboratories, Watson Pharmaceuticals, Lupin, Orchid Chemical & Pharmaceuticals and others, had either submitted files to the Food and Drug Administration indicating that they were going to supply carvedilol or had received tentative FDA approval to market generic drugs containing it.

The court has dismissed the case without costs or prejudice, allowing it to be reopened in 60 days if the settlement isn’t carried out.